

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	General
Galderma (nemolizumab)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Changing Faces	Wales
 Eczema Outreach Support 	British National Formulary
Let's Face It	Care Quality Commission
 National Eczema Society 	Department of Health, Social Services
 Prurigo Nodularis International 	and Public Safety for Northern Ireland
 South Asian Health Foundation 	Healthcare Improvement Scotland
Specialised Healthcare Alliance	 Medicines and Healthcare products Regulatory Agency
Healthcare professional groups	National Association of Primary Care
British Association of Dermatologists	 National Pharmacy Association
British Dermatological Nursing Group	NHS Confederation
British Geriatrics Society	Scottish Medicines Consortium
British Skin Foundation	Welsh Government
 British Society for Cutaneous Allergy 	Welsh Health Specialised Services
 Neonatal and Paediatric Pharmacists Group 	Committee
Primary Care Dermatology Society	Possible comparator companies
Royal College of General Practitioners	Abbvie (upadacitinib)
Royal College of Nursing	 Advanz Pharma (methotrexate
Royal College of Paediatrics and Child Health	 Aspen (azathioprine, mycophenolate mofetil)
Royal College of Pathologists	Cipla ÚK (methotrexate
Royal College of Physicians	Dexcel harma (ciclosporin)
Royal Pharmaceutical Society	Eli Lilly (baricitinib)
Royal Society of Medicine	Hospira (methotrexate)
St John's Institute of Dermatology	LeoLaboratories (tralokinumab)
UK Clinical Pharmacy Association	Medac (methotrexate
	Morningside Healhcare (methotrexate

Provisional stakeholder list for the evaluation of nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221 Issue date: May 2024



Consultees	Commentators (no right to submit or appeal)
Others Department of Health and Social Care NHS England	 Mylan (azathioprine; ciclosporin, mycophenolate mofetil) Nordic Pharma (methotrexate) Nova (azathioprine; mycophenolate mofetil) Novartis Pharmaceuticals (ciclosporin) Orion Pharma (methotrexate) Pfizer (abrocitinib; Rosemont Pharmaceuticals (methotrexate) Sandoz (methotrexate) Santen UK (ciclosporin) Strides Pharma (azathioprine, mycophenolate mofetil) Tillomed Laboratories (azathioprine, mycophenolate mofetil)
	Relevant research groups Centre of Evidence-based Dermatology, University of Nottingham Cochrane Skin Group Dermatrust Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221 Issue date: May 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.